Related Experiment Video

Updated: Apr 6, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

18.9K

Psychopathological comorbidities in medication-overuse headache: a multicentre clinical study

P Sarchielli1, I Corbelli1, P Messina2

  • 1Clinica Neurologica, Azienda Ospedaliero - Universitaria di Perugia, Perugia, Italy.

European Journal of Neurology
|August 1, 2015
PubMed
Abstract

Insights

Medication-overuse headache (MOH) patients exhibit more psychopathological comorbidities than episodic migraine (EM) patients or healthy controls (HC). Assessing these disorders is crucial for effective MOH treatment and management.

Area of Science:

  • Neurology
  • Psychiatry
  • Clinical Psychology

Background:

  • Medication-overuse headache (MOH) is a complex condition.
  • Psychopathological disturbances are suspected predictors of MOH relapse and treatment resistance.

Purpose of the Study:

  • To determine the prevalence of psychopathological disorders in MOH patients.
  • To compare psychopathological profiles between MOH, episodic migraine (EM), and healthy controls (HC).

Main Methods:

  • Utilized validated questionnaires: Beck Depression Inventory, Beck Anxiety Inventory, M-MINI, Y-BOCS, and Leeds Dependence Questionnaire.
  • Assessed psychopathology in 88 MOH patients, 129 EM patients, and 102 HC subjects.

Main Results:

  • MOH patients showed significantly higher rates of moderate/severe anxiety compared to EM and HC groups.
  • MOH patients presented a more complex psychiatric comorbidity profile.
  • Obsessive-compulsive disturbances related to drug abuse were more prevalent in MOH patients than in EM or HC groups.

Conclusions:

  • Psychopathological comorbidities are frequently observed in MOH patients.
  • Routine assessment of psychopathological profiles in MOH patients is recommended.
  • Integrating behavioral treatments can significantly improve MOH management.
Keywords:
case-control studiesheadachemedication-overuse headachemigraineobsessive−compulsive disturbancespsychiatric disorders

More Related Videos

Investigating Migraine-Like Behavior Using Light Aversion in Mice05:23

Investigating Migraine-Like Behavior Using Light Aversion in Mice

Published on: August 11, 2021

4.6K
Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study07:30

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

8.1K

Related Concept Videos

Substance Use Disorders Affecting Sleep01:24

Substance Use Disorders Affecting Sleep

Substance use disorders involve a pattern of using drugs more extensively than intended and continuing use despite harmful consequences. This includes legal substances like alcohol and nicotine, as well as illegal drugs. These disorders often involve both physical and psychological dependence, reflecting compulsive use of substances that significantly alter thoughts, feelings, and behaviors, contributing to a major public health issue.
Understanding the concepts of physical dependence,...
549
Drug Abuse and Addiction: Pharmacological Phenomena01:15

Drug Abuse and Addiction: Pharmacological Phenomena

Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
1.5K
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.2K
Toxidromes: Clinical Features01:30

Toxidromes: Clinical Features

Toxidromes are specific patterns of symptoms resulting from toxic substance exposure. They help in the identification and treatment of poisoning. The symptoms of each toxidrome group indicate poisoning by a certain class of chemicals or drugs.1. Sympathomimetic: Stimulates the sympathetic nervous system. Symptoms include agitation, increased heart rate (HR), blood pressure (BP), respiratory rate (RR), temperature, and pupil size. Drugs like cocaine and amphetamines, along with tremors and...
128
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
729
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
339